Rejection and acceptance of possible side effects of migraine prophylactic drugs: Research submission

Headache

Volumn 49, Issue 7, 2009, Pages 1022-1027

  Kowacs, Pedro A ^a,b   Piovesan, Elcio J ^b   Tepper, Stewart J ^c  

^a INSTITUTO DE NEUROLOGIA DE CURITIBA   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adverse events; Migraine; Patient preference; Prevention; Prophylaxis; Side effects

Indexed keywords

ANTIMIGRAINE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYPROHEPTADINE; FLUNARIZINE; PIZOTIFEN; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADULT; AGED; AMNESIA; ARTICLE; ASTHENIA; DEPRESSION; EPIGASTRIC BURNING; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RATING SCALE; SIDE EFFECT; SKIN TINGLING; SLUGGISHNESS; SOMNOLENCE; TREMOR; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANALGESICS; CLUSTER ANALYSIS; DEPRESSION; FEMALE; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT COMPLIANCE; SEX CHARACTERISTICS; WEIGHT GAIN; YOUNG ADULT;

EID: 67651159274     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2009.01431.x     Document Type: Article

References (16)

1. Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006 26 : 188 198.
2. Rozen TD. Migraine prevention: What patients want from medication and their physicians (a Headache Specialty Clinic perspective). Headache. 2006 46 : 750 753.
3. Peres MFP, Silberstein S, Moreira F, et al. Patients' preference for migraine preventive therapy. Headache. 2007 47 : 540 545.
4. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders : 2nd edn. Cephalalgia 2004 24 (Suppl. 1 9 160.
5. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 26 : 742 746.
6. Breivik H, Borchgrevink PC, Allen SM, et al. Assessment of pain. Br J Anaesth. 2008 101 : 17 24.
7. Gingras J. Body image dissatisfaction: A framework of development and recommendations for dietitians. Can J Diet Pract Res. 1998 59 : 132 137.
8. Wolkenstein L, Meyer TD. Attitudes of young people towards depression and mania. Psychol Psychother. 2008 81 : 15 31.
9. Laforce R Jr., McLean S. Knowledge and fear of developing Alzheimer's disease in a sample of healthy adults. Psychol Rep. 2005 96 : 204 206.
10. Moore S, Knowles S. Beliefs and knowledge about Parkinson's disease. J Appl Psychol: Clin Soc Issues. 2006 2 : 15 21.
11. Micheli FE, Pardal MM, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord. 1989 4 : 139 146.
12. Klapper J. Divalproex sodium in migraine prophylaxis: A dose-controlled study. Cephalalgia. 1997 17 : 103 108.
13. Young WB, Rozen TD. Preventive treatment of migraine: Effect on weight. Cephalalgia. 2005 25 : 1 11.
14. Martin R, Kuzniecky R, Ho S, et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology. 1999 52 : 321 327.
15. Tietjen GE, Herial NA, Hardgrove J, Utley C, White L. Migraine comorbidity constellations. Headache. 2007 47 : 857 865.
16. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C. Satisfaction with current migraine therapy: Experience from 3 centers in US and Sweden. Headache. 2007 47 : 475 479.